Summary
Redirect | ||||
---|---|---|---|---|
|
Excerpt |
---|
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with incidences doubled over the past two decades due to increasing risk factors. Despite surveillance, the majority of HCC cases are diagnosed at advanced stages that can be treated only using (Transarterial chemoembolization) TACE, or systemic therapy. TACE failure can occur to 60% of patients receiving the procedure, with subsequent financial and emotional burden. Radiomics have emerged as a new tool capable of predicting tumor response to TACE from pre-procedural CT study. This retrospectively acquired data collection includes pre- and post-procedure CT imaging studies of 105 confirmed HCC patients who underwent TACE between 2002 and 2012 with an available treatment outcome, in the form of time-to-progression and overall survival. Baseline imaging includes multiphasic contrast-enhanced CT with no image artifacts (e.g. surgical clip) and was obtained 1-12 weeks (average 3 weeks) prior to the first TACE session. Semiautomatic segmentation of liver, tumor, and blood vessels created using AMIRA was manually clinically curated. These segmentations of each pre-procedural CT study were done for the purpose of algorithm training for prediction and automatic liver tumor segmentation, and are provided here (NIfTI converted to DICOM-SEG format) |
Excerpt |
This dataset was retrospectively acquired from University of Texas - MD Anderson cancer center, after its IRB approval. It contains patients treated at MD Anderson with hepatocellular carcinoma from November 2002 to June 2012. The inclusion criteria were TACE as the sole first-line or initial bridging therapy and availability of multiphasic contrast material–enhanced CT images obtained at baseline with no image artifacts (eg, surgical clips). On average, baseline CT was performed 3 weeks before the first session of TACE (range, 1–12 weeks). Segmentation (liver, tumor, vessels) were created with semiautomated software in NIfTI and converted to DICOM SEG format. |
Acknowledgements
We would like to acknowledge the individuals and institutions that have provided data for this collection:
The University of Texas MD Anderson Cancer Center, Departments of Imaging Physics, Body Imaging, Gastrointestinal Oncology, Epidemiology, and Interventional Radiology.
Hospital/Institution Name city, state, country - Special thanks to First Last Names, degree PhD, MD, etc from the Department of xxxxxx, Additional Names from same location.
- Continue with any names from additional submitting sites if collection consists of more that one.
Harmonization of the components of this dataset, including into standard DICOM representation, was supported in part by the NCI Imaging Data Commons consortium. NCI Imaging Data Commons consortium is supported by the contract number 19X037Q from Leidos Biomedical Research under Task Order HHSN26100071 from NCI.
Localtab Group | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|